Clinical Trials

RTOG 0513:
A Study Adding an Investigational Drug to Standard Care for Treatment of Newly Diagnosed Glioblastoma Multiforme

The purpose of this study is to find out what effects (good and bad) radiation therapy combined with temozolomide and motexafin gadolinium have on Glioblastoma Multiforme. Motexafin gadolinium, or MGd, is a drug that builds up in cancer cells. In earlier studies using MGd in patients with brain tumors, more drug stayed in the cancer cells than in the normal cells. MGd may weaken cancer cells and help some types of chemotherapy and radiotherapy work better. MGd is an investigational drug that has not been approved by the FDA for treating brain tumors. Temozolomide is a chemotherapy agent approved by the FDA for treating some brain tumors. The standard treatment for a GBM is a combination of surgery, radiation therapy, and chemotherapy. Although there are treatments for newly diagnosed GBM, they are not curative. This research is being done because currently there is no curative treatment for newly diagnosed GBM.

For more info, contact Cindy Gu at 585-275-2525